Thrombin generation profile in non-thrombotic factor V Leiden carriers.


Journal

Journal of thrombosis and thrombolysis
ISSN: 1573-742X
Titre abrégé: J Thromb Thrombolysis
Pays: Netherlands
ID NLM: 9502018

Informations de publication

Date de publication:
Apr 2019
Historique:
pubmed: 1 2 2019
medline: 23 7 2019
entrez: 1 2 2019
Statut: ppublish

Résumé

Factor V Leiden (FVL) mutation is the most common genetic risk factor for venous thromboembolism. In families with a history of thrombosis, FVL can be present in 18%. Thrombin generation test is commonly used as an evaluation tool of thrombotic risk. The objective of this study was to evaluate the thrombogenic potential of FVL in asymptomatic carriers and in patients with personal or familial history of thrombosis. This was a retrospective single center study including 160 patients. Among them, 43 had personal history of thrombosis and 117 had familial history of thrombosis. Thrombin generation (TG) was realized in frozen platelet poor plasma with 1 pM of tissue factor and 4 µM of phospholipid. FVL mutation was associated with a global increase of TG. No difference was observed between patients with provoked thrombosis and patients with first-degree familial history of thrombosis (endogenous thrombin potential (ETP): 1501.0 ± 316.4 nM min and thrombin peak: 253.4 ± 71.5 nM vs. 1520.4 ± 283.8 nM min and 268.6 ± 68.0 nM). An increase of TG was observed in patients with unprovoked thrombosis (n = 23) and in patients with provoked thrombosis (n = 20) (ETP: 1819.5 ± 319.8 nM min and peak: 332.3 ± 55.8 nM). In the unprovoked thrombosis group, patients with a pulmonary embolism had a higher ETP than patients with deep vein thrombosis (DVT) (2036 ± 343 nM min vs. 1707 ± 261 nM min). With a predictive score formula (s = 0.1315 × Age + 0.0105 × ETP) with a threshold of 22.1 as risk to develop an unprovoked thrombosis among patients with second-degree familial history. The results of our analysis suggest that measurement of thrombin generation in patients with FVL mutation may identify subjects with an increased risk of unprovoked thrombosis. Further studies are needed to examine the usefulness of predicting thrombotic presentation in asymptomatic carriers.

Identifiants

pubmed: 30701464
doi: 10.1007/s11239-019-01821-0
pii: 10.1007/s11239-019-01821-0
doi:

Substances chimiques

factor V Leiden 0
Factor V 9001-24-5
Thrombin EC 3.4.21.5

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

473-477

Références

Thromb Haemost. 2006 Nov;96(5):553-61
pubmed: 17080210
Thromb Res. 2009 Jun;124(2):178-84
pubmed: 19232683
Arch Intern Med. 2009 Mar 23;169(6):610-5
pubmed: 19307525
JAMA. 2009 Jun 17;301(23):2472-85
pubmed: 19531787
BMC Bioinformatics. 2011 Mar 17;12:77
pubmed: 21414208
Blood. 2012 Aug 2;120(5):933-46
pubmed: 22496157
Nat Rev Cardiol. 2015 Aug;12(8):464-74
pubmed: 26076949
Expert Rev Hematol. 2016 Dec;9(12):1139-1149
pubmed: 27797270
Lancet. 1995 Oct 28;346(8983):1133-4
pubmed: 7475606
Blood. 1996 Dec 1;88(11):4205-8
pubmed: 8943855
Thromb Haemost. 1997 Apr;77(4):629-36
pubmed: 9134633
Semin Thromb Hemost. 1998;24(4):367-79
pubmed: 9763354

Auteurs

Paul Billoir (P)

Normandie Univ, UNIROUEN, INSERM U1096, Rouen University Hospital, Vascular Hemostasis Unit, F 76000, Rouen, France. paul.billoir@chu-rouen.fr.
Service d'Hématologie Biologique, Centre Hospitalier Universitaire Charles Nicolle, 1 rue de Germont, 76031, Rouen, France. paul.billoir@chu-rouen.fr.

Thomas Duflot (T)

Department of Pharmacology, CHU de Rouen, 76000, Rouen, France.
INSERM U1096, Normandie University, UNIROUEN, 76000, Rouen, France.

Marielle Fresel (M)

Rouen University Hospital, Vascular Hemostasis Unit, F 76000, Rouen, France.

Marie Hélène Chrétien (MH)

Rouen University Hospital, Vascular Hemostasis Unit, F 76000, Rouen, France.

Virginie Barbay (V)

Rouen University Hospital, Vascular Hemostasis Unit, F 76000, Rouen, France.

Véronique Le Cam Duchez (V)

Normandie Univ, UNIROUEN, INSERM U1096, Rouen University Hospital, Vascular Hemostasis Unit, F 76000, Rouen, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH